WHO grants 'emergency validation' to Pfizer-BioNTech vaccine

File: A healthcare worker prepares a dose of the Pfizer-BioNtech COVID-19 vaccine. AFP/Jack Guez

GENEVA - The World Health Organization granted emergency validation to the Pfizer-BioNTech vaccine, paving the way for countries worldwide to quickly approve its import and distribution

WHO said the Pfizer/BioNTech vaccine was the first to receive its "emergency validation" since the novel coronavirus first broke out in China a year ago.

"This is a very positive step towards ensuring global access to COVID-19 vaccines," said Mariangela Simao, a top WHO official tasked with ensuring access to medicines.

READ: Civil society organisations call for fair distribution of COVID-19 vaccine

"But I want to emphasise the need for an even greater global effort to achieve enough vaccine supply to meet the needs of priority populations everywhere," she said in a statement.

WHO said its emergency use listing opens the way for regulators in different countries to approve the import and distribution of the vaccine.

READ: Criticism over COVID-19 vaccine delay mounts

It said it also enables UNICEF, which plays a key logistical role in distributing anti-Covid vaccines, and the Pan-American Health Organization to procure the vaccine for countries that need it.

WHO convened its own experts and those from around the world to review the data on the Pfizer/BioNTech vaccine’s "safety, efficacy and quality," weighing the benefits against the risks.

"The review found that the vaccine met the must-have criteria for safety and efficacy set out by WHO, and that the benefits of using the vaccine to address COVID-19 offset potential risks," it said.

Source
AFP

Paid Content